Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer.
about
Rho-associated kinase signalling and the cancer microenvironment: novel biological implications and therapeutic opportunitiesHigh Potency VEGFRs/MET/FMS Triple Blockade by TAS-115 Concomitantly Suppresses Tumor Progression and Bone Destruction in Tumor-Induced Bone Disease Model with Lung Carcinoma Cells.Quantitative imaging for development of companion diagnostics to drugs targeting HGF/MET.Targeted molecular-genetic imaging and ligand-directed therapy in aggressive variant prostate cancer.Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma.Targeting Met and VEGFR Axis in Metastatic Castration-Resistant Prostate Cancer: 'Game Over'?Identification of Bone-Derived Factors Conferring De Novo Therapeutic Resistance in Metastatic Prostate Cancer.MET expression during prostate cancer progression.Cabozantinib-induced osteoblast secretome promotes survival and migration of metastatic prostate cancer cells in bone.BIGH3 Promotes Osteolytic Lesions in Renal Cell Carcinoma Bone Metastasis by Inhibiting Osteoblast Differentiation.Bone-Targeted Therapies in Cancer-Induced Bone Disease.Current perspectives on bone metastases in castrate-resistant prostate cancer.
P2860
Q26778344-FFA354D3-89CB-413C-9792-CB8C9E41BBD9Q36162776-8E451CBF-4E2A-4DC0-B36E-6E2380AF6745Q37346559-96FBC00F-6D96-45EA-8FDA-4A91A4CDCE57Q37417870-CF129D2A-37BB-41EC-8EE9-3C49766053C5Q37672483-07A54653-9940-417C-A246-301CAD8D9983Q38723404-FEB3C563-8F0C-49A9-80C7-DA29085798F8Q38822335-BDC68DBD-320F-41A8-B485-E7548425A12BQ41418443-3BC652A3-FE80-41B6-866E-4B16BE3BAFE3Q44676922-7278ECAB-4B3A-4F20-8B4D-8FE4AC06BC7FQ47129742-5BFBA4E6-29C8-46A0-BB51-81CE57124BFEQ48110513-A0CC6F97-95C3-47D8-B188-B5EECADB90AFQ49285273-18EF2D5F-8E0C-4BDB-9520-C35E3D63134A
P2860
Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Integrating Murine and Clinica ...... Inhibition of Prostate Cancer.
@ast
Integrating Murine and Clinica ...... Inhibition of Prostate Cancer.
@en
type
label
Integrating Murine and Clinica ...... Inhibition of Prostate Cancer.
@ast
Integrating Murine and Clinica ...... Inhibition of Prostate Cancer.
@en
prefLabel
Integrating Murine and Clinica ...... Inhibition of Prostate Cancer.
@ast
Integrating Murine and Clinica ...... Inhibition of Prostate Cancer.
@en
P2093
P2860
P1476
Integrating Murine and Clinica ...... Inhibition of Prostate Cancer.
@en
P2093
Ana Aparicio
Andreas Varkaris
Anh G Hoang
Bogdan A Czerniak
Christopher J Logothetis
Eleni Efstathiou
Gary E Gallick
Jian H Song
Lynnelle Thorpe
Menashe Bar Eli
P2860
P304
P356
10.1158/1078-0432.CCR-15-0235
P407
P577
2015-08-13T00:00:00Z